PTC Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$56.6M
Doctors Paid
1,083
Transactions
9,790
2024 Total
$8.4M
Payment Breakdown by Category
Research$49.2M (87.0%)
Consulting$2.8M (4.9%)
Royalty/License$482,303 (0.9%)
Travel$294,283 (0.5%)
Food & Beverage$98,485 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $49.2M | 5,286 | 87.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.5M | 340 | 6.3% |
| Consulting Fee | $2.8M | 697 | 4.9% |
| Royalty or License | $482,303 | 20 | 0.9% |
| Travel and Lodging | $294,283 | 605 | 0.5% |
| Food and Beverage | $98,485 | 2,433 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $71,845 | 42 | 0.1% |
| Education | $54,467 | 356 | 0.1% |
| Grant | $11,675 | 8 | 0.0% |
| Charitable Contribution | $7,000 | 3 | 0.0% |
Payments by Type
Research
$49.2M
5,286 transactions
General
$7.3M
4,504 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UNESBULIN IN UNRESECTABLE OR METASTATIC, RELAPSED OR REFRACTORY LEIOMYOSARCOMA | $6.9M | 9 | 556 |
| AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | $2.5M | 0 | 794 |
| AN OPEN-LABEL TRIAL TO ADDRESS THE SAFETY OF THE SMARTFLOW MR-COMPATIBLE VENTRICULAR CANNULA FOR ADMINISTERING ELADOCAGENE EXUPARVOVEC TO PEDIATRIC SUBJECTS | $2.4M | 3 | 98 |
| TQT STUDY - PHASE 1 PLACEBO AND POSITIVE CONTROLLED STUDY TO ASSESS THE EFFECT OF SINGLE THERAPEUTIC (400 MG) AND SUPRATHERAPEUTIC VATIQUINONE (1200 MG) DOSES ON QTCF PROLONGATION BY USING CONCENTRATION-EFFECT MODELLING (CEM) | $2.1M | 0 | 18 |
| EFFICACY AND SAFETY STUDY OF VATIQUINONE FOR THE TREATMENT OF MITOCHONDRIAL DISEASE SUBJECTS WITH REFRACTORY EPILEPSY | $2.0M | 2 | 463 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ATALUREN IN PATIENTS WITH NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY AND OPEN-LABEL EXTENSION | $1.8M | 0 | 450 |
| A PHASE IB STUDY OF PTC596 IN CHILDREN WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA AND HIGH GRADE GLIOMA | $1.8M | 0 | 39 |
| AN OPEN-LABEL, SAFETY STUDY FOR PREVIOUSLY TREATED VATIQUINONE (PTC743) SUBJECTS WITH INHERITED MITOCHONDRIAL DISEASE | $1.7M | 0 | 267 |
| AN OPEN-LABEL TRIAL TO ADDRESS THE SAFETY OF THE SMARTFLOW MR COMPATIBLE VENTRICULAR CANNULA FOR ADMINISTERING ELADOCAGENE EXUPARVOVEC TO PEDIATRIC SUBJECTS | $1.6M | 3 | 33 |
| A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA (MOVE-FA) | $1.5M | 2 | 183 |
| A PHASE 1B STUDY OF UNESBULIN (PTC596) IN COMBINATION WITH DACARBAZINE IN PATIENTS WITH LOCALLY RECURRENT, UNRESECTABLE OR METASTATIC RELAPSED/REFRACTORY LEIOMYOSARCOMA | $1.5M | 0 | 92 |
| PHASE 1B STUDY OF PTC299 IN RELAPSED/REFRACTORY ACUTE LEUKEMIAS | $1.2M | 0 | 155 |
| AN OPEN-LABEL, SAFETY STUDY FOR PREVIOUSLY TREATED ATALUREN PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | $1.2M | 0 | 248 |
| PHASE 1 STUDY TO INVESTIGATE THE ABSORPTION, METABOLISM, AND EXCRETION OF 14C PTC923 FOLLOWING A SINGLE ORAL DOSE ADMINISTRATION IN HEALTHY MALE VOLUNTEERS | $1.2M | 0 | 10 |
| PHASE 2 CLINICAL PHARMACOLOGY STUDY TO ASSESS DYSTROPHIN LEVELS IN SUBJECTS WITH NMDMD BEFORE AND AFTER TREATMENT WITH ATALUREN | $1.1M | 0 | 87 |
| A PHASE 1 STUDY TO INVESTIGATE THE PHARMACOKINETICS OF PTC743 AND THE ABSORPTION, METABOLISM, AND EXCRETION OF 14C-PTC743 IN HEALTHY VOLUNTEERS | $1.0M | 0 | 9 |
| A PHASE 3 STUDY OF PTC923 IN SUBJECTS WITH PHENYLKETONURIA | $970,020 | 0 | 74 |
| A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA | $896,011 | 0 | 44 |
| AN OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, TWO-PERIOD CROSSOVER STUDY COMPARING THE BIOEQUIVALENCE OF DEFLAZACORT DISPERSIBLE TABLET TO EMFLAZA DEFLAZACORT TABLET IN HEALTHY ADULT SUBJECTS | $869,415 | 0 | 8 |
| A PHASE 1B STUDY OF PTC596 IN COMBINATION WITH DACARBAZINE IN PATIENTS WITH LOCALLY RECURRENT, UNRESECTABLE OR METASTATIC RELAPSED-REFRACTORY LEIOMYOSARCOMA | $766,581 | 0 | 72 |
| A PHASE 3 OPEN-LABEL STUDY OF PTC923 (SEPIAPTERIN) IN PHENYLKETONURIA | $738,581 | 0 | 55 |
| NELSON OBSERVATIONAL STUDY | $733,501 | 0 | 7 |
| Phase 1 open label single dos 4-group study to eveluate the PK and Safety of Ataluren in subjects with various severities of impaired Hepatic Function and healthy subjects | $704,260 | 0 | 6 |
| A PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE ABSORPTION, METABOLISM, AND EXCRETION OF 14C-PTC518 IN HEALTHY MALE PARTICIPANTS | $641,294 | 0 | 6 |
| Open-Label, Safety Study for Previously Treated Ataluren (PTC124) Patients with Nonsense Mutation Dystrophinopathy in North America | $570,036 | 0 | 84 |
| LONG-TERM OPEN-LABEL STUDY TO ASSESS THE SAFETY AND EFFICACY OF VATIQUINONE IN PATIENTS WITH FRIEDREICH ATAXIA | $527,481 | 0 | 120 |
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OF PTC857 IN ADULT SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (CARDINALS) | $523,990 | 3 | 99 |
| A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN | $521,334 | 0 | 35 |
| EVALUATING THE THERAPEUTIC POTENTIAL OF MAPT SPLICING MODULATIONIN HUMAN NEURONAL MODELS OF TAUOPATHY | $475,400 | 0 | 4 |
| A Phase 1 Study to investigate the absorption and metabolism of 14-C deflazacort following single oral dose administration in healthy subjects | $416,003 | 0 | 9 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Robert Spiegel, M.d, M.D | Contractor | Westfield, NJ | $1.0M | $0 |
| Dr. Glenn Steele, M.d, M.D | Surgery | Danville, PA | $473,856 | $0 |
| Ashutosh Kumar, M.d, M.D | Student in an Organized Health Care Education/Training Program | Hershey, PA | $98,866 | $0 |
| Dr. Craig Mcdonald, M.d, M.D | Pediatric Rehabilitation Medicine | Sacramento, CA | $96,765 | $0 |
| Stanley Nelson, Md, MD | Pediatrics | Los Angeles, CA | $61,567 | $0 |
| Timothy Feyma, Md, MD | Neurology with Special Qualifications in Child Neurology | Bloomington, MN | $56,143 | $0 |
| John Brandsema, Md, MD | Neurology with Special Qualifications in Child Neurology | Philadelphia, PA | $53,680 | $0 |
| Dr. Diana Castro, Md, MD | Student in an Organized Health Care Education/Training Program | Denton, TX | $50,368 | $0 |
| Michael Kruer, M.d, M.D | Neurodevelopmental Disabilities | Phoenix, AZ | $50,189 | $0 |
| Dr. Nicola Longo, Md, MD | Clinical Biochemical Genetics | Los Angeles, CA | $49,405 | $0 |
| Kan Hor, M.d, M.D | Pediatric Critical Care Medicine | Columbus, OH | $44,808 | $0 |
| Jennifer O'malley, Md, Phd, MD, PHD | Pediatrics | Palo Alto, CA | $44,640 | $0 |
| John Jay Gargus, Md, MD | Clinical Genetics (M.D.) | Orange, CA | $44,011 | $0 |
| Jonathan Mink, Md, Phd, MD, PHD | Neurology with Special Qualifications in Child Neurology | Rochester, NY | $37,600 | $0 |
| Irina Anselm, M.d, M.D | Neurology with Special Qualifications in Child Neurology | Boston, MA | $33,229 | $0 |
| Dr. Berrin Monteleone, Md, MD | Clinical Genetics (M.D.) | Mineola, NY | $33,204 | $0 |
| Daniel Claassen, M.d, M.D | Neurology | Nashville, TN | $31,693 | $0 |
| Dr. Aravindhan Veerapandiyan, Md, MD | Neurology with Special Qualifications in Child Neurology | Little Rock, AR | $30,960 | $0 |
| Melissa Lah, Md, MD | Clinical Genetics (M.D.) | Indianapolis, IN | $29,770 | $0 |
| Andrew Feigin, Md, MD | Neurology | New York, NY | $29,025 | $0 |
| Barbara Burton, Md, MD | Clinical Genetics (M.D.) | Chicago, IL | $28,792 | $0 |
| David Gonda, M.d, M.D | Neurological Surgery | San Diego, CA | $28,708 | $0 |
| Warren Marks, Md, MD | Pediatrics | Fort Worth, TX | $27,791 | $0 |
| Lauren Elman, Md, MD | Neurology | Philadelphia, PA | $26,885 | $0 |
| Erika Augustine, Md, MD | Neurology with Special Qualifications in Child Neurology | Rochester, NY | $25,600 | $0 |
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc. has made $56.6M in payments to 1,083 healthcare providers, recorded across 9,790 transactions in the CMS Open Payments database. In 2024, the company paid $8.4M. The top product by payment volume is EMFLAZA ($1.3M).
Payments were distributed across 89 medical specialties. The top specialty by payment amount is Contractor ($1.0M to 1 doctors).
Payment categories include: Food & Beverage ($98,485), Consulting ($2.8M), Research ($49.2M), Travel & Lodging ($294,283), Royalties ($482,303).
PTC Therapeutics, Inc. is associated with 2 products in the CMS Open Payments database.